Key facts
CAS number:107868-30-4,
Purity:>99%,
Form:SolidSee storage information,
Molecular weight:296.4 Da,
Molecular formula:C20H24O2,
PubChem:60198,
Nature:Synthetic,
Solubility:Soluble in DMSO to 100 mMSoluble in ethanol to 75 mM,
Biochemical name:Exemestane,
Biological description:Irreversible, orally active, steroidal aromatase (CYP19) inhibitor (Ki = 26 nM). Anticancer activity in vitro and in vivo, effective against breast cancer.,
Canonical smiles:CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C,
Isomeric smiles:C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C,
InChi:InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1,
InChiKey:BFYIZQONLCFLEV-DAELLWKTSA-N,
IUPAC Name:(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store under desiccating conditions, The product can be stored for up to 12 months
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The biological targets Estrogen Receptor (ER) Gli3 TDP1 Androgen Receptor (AR) PXR Estrogen Related Receptor alpha (ERRα) Aromatase and Nrf2 play significant roles in cellular function. Aromatase also known as CYP19 is an enzyme that catalyzes the conversion of androgens to estrogens. It is expressed in the ovaries testes brain and adipose tissue. It is a cytochrome P450 enzyme with a mass of approximately 58 kDa. Aromatase exists as part of larger protein complexes and is important in maintaining estrogen levels in the body. A popular inhibitor of aromatase is exemestane which modulates this conversion by binding to the aromatase structure.
Biological function summary
These targets are important in hormonal regulation and metabolic processes. Estrogen and androgen receptors for example bind to their respective hormones influencing gene expression and cell behavior. Estrogen-related receptor alpha acts without direct ligand binding but impacts similar pathways. Meanwhile Aromatase often part of the ER complex serves essential functions in steroid hormone biosynthesis by facilitating the aromatization of androgens. As modulators of gene expression these proteins influence numerous biochemical cascades. Exemestane price and buy concerns stem from its application in modulating aromatase activity highlighting its pharmaceutical importance particularly in conditions driven by hormonal dynamics.
Pathways
These proteins interact within major signaling cascades such as the steroid hormone biosynthesis pathway and the carbohydrate response element-binding protein (ChREBP) pathway. Aromatase (CYP19) contributes to estrogen biosynthesis by converting testosterone and other androgens linking to pathways involving estrogen receptor signaling. This interaction with ER and AR highlights their collective roles in cellular proliferation and differentiation. Nrf2 primarily known for its actions in oxidative stress responses intersects with these pathways to modulate cellular antioxidant defenses illustrating a relationship with metabolic balance facilitated by similar physiological mechanisms.
These targets align with various cancers and endocrine disorders. Estrogen Receptor and Aromatase are notably involved in breast cancer where excessive estrogen production and receptor overexpression drive tumor growth. Aromatase inhibitors like exemestane manage hormone-responsive cancers by reducing estrogen synthesis. Androgen Receptor plays a critical role in prostate cancer influencing disease progression by mediating testosterone-driven signals. Through these disease associations the interplay between proteins like Gli3 and TDP1 also emerges tied to pathways that may contribute to cancerous transformations as well as genomic instability and repair mechanisms.
